Innoviva, Inc.’s (NASDAQ:INVA) Low P/S No Reason For Excitement

Innoviva, Inc.’s (NASDAQ:INVA) price-to-sales (or “P/S”) ratio of 3.6x might make it look like a buy right now compared to the Pharmaceuticals industry in the United States, where around half of the companies have P/S ratios above 4.5x and even P/S above 15x are quite common. Although, it’s not wise to just take the P/S at face value as there may be an explanation why it’s limited.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

Check out our latest analysis for Innoviva

What Does Innoviva’s Recent Performance Look Like?

There hasn’t been much to differentiate Innoviva’s and the industry’s revenue growth lately. One possibility is that the P/S ratio is low because investors think this modest revenue performance may begin to slide. If you like the company, you’d be hoping this isn’t the case so that you could pick up some stock while it’s out of favour.

Keen to find out how analysts think Innoviva’s future stacks up against the industry? In that case, our free report is a great place to start.

How Is Innoviva’s Revenue Growth Trending?

In order to justify its P/S ratio, Innoviva would need to produce sluggish growth that’s trailing the industry.

Taking a look back first, we see that the company grew revenue by an impressive 19% last year. Despite this strong recent growth, it’s still struggling to catch up as its three-year revenue frustratingly shrank by 6.7% overall. So unfortunately, we have to acknowledge that the company has not done a great job of growing revenues over that time.

Looking ahead now, revenue is anticipated to climb by 11% per annum during the coming three years according to the sole analyst following the company. Meanwhile, the rest of the industry is forecast to expand by 19% per year, which is noticeably more attractive.

In light of this, it’s understandable that Innoviva’s P/S sits below the majority of other companies. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.

The Bottom Line On Innoviva’s P/S

Typically, we’d caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

As we suspected, our examination of Innoviva’s analyst forecasts revealed that its inferior revenue outlook is contributing to its low P/S. Shareholders’ pessimism on the revenue prospects for the company seems to be the main contributor to the depressed P/S. The company will need a change of fortune to justify the P/S rising higher in the future.

You always need to take note of risks, for example – Innoviva has 1 warning sign we think you should be aware of.

If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.